{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:25:04Z","timestamp":1780550704858,"version":"3.54.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Swedish Foundation of Strategic Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims\u2003<\/jats:title>\n                  <jats:p>There is a paucity of studies comprehensively comparing the prognostic value of larger arrays of biomarkers indicative of different pathobiological axes in acute myocardial infarction (MI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results\u2003<\/jats:title>\n                  <jats:p>In this explorative investigation, we simultaneously analysed 175 circulating biomarkers reflecting different inflammatory traits, coagulation activity, endothelial dysfunction, atherogenesis, myocardial dysfunction and damage, apoptosis, kidney function, glucose-, and lipid metabolism. Measurements were performed in samples from 1099 MI patients (SWEDEHEART registry) applying two newer multimarker panels [Proximity Extension Assay (Olink Bioscience), Multiple Reaction Monitoring mass spectrometry]. The prognostic value of biomarkers regarding all-cause mortality, recurrent MI, and heart failure hospitalizations (median follow-up \u22646.6\u2009years) was studied using Lasso analysis, a penalized logistic regression model that considers all biomarkers simultaneously while minimizing the risk for spurious findings. Tumour necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2), ovarian cancer-related tumour marker CA 125 (CA-125), and fibroblast growth factor 23 (FGF-23) consistently predicted all-cause mortality in crude and age\/sex-adjusted analyses. Growth-differentiation factor 15 (GDF-15) was strongly predictive in the crude model. TRAIL-R2 and B-type natriuretic peptide (BNP) consistently predicted heart failure hospitalizations. No biomarker predicted recurrent MI. The prognostic value of all biomarkers was abrogated following additional adjustment for clinical variables owing to our rigorous statistical approach.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion\u2003<\/jats:title>\n                  <jats:p>Apart from biomarkers with established prognostic value (i.e. BNP and to some extent GDF-15), several \u2018novel\u2019 biomarkers (i.e. TRAIL-R2, CA-125, FGF-23) emerged as risk predictors in patients with MI. Our data warrant further investigation regarding the utility of these biomarkers for clinical decision-making in acute MI.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjacc\/zuaa014","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T05:59:46Z","timestamp":1623131986000},"page":"806-812","source":"Crossref","is-referenced-by-count":16,"title":["Predicting outcome in acute myocardial infarction: an analysis investigating 175 circulating biomarkers"],"prefix":"10.1093","volume":"10","author":[{"given":"Kai M","family":"Eggers","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala 751 85, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Lindhagen","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Baron","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala 751 85, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Erlinge","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Sciences, Lund University, Sk\u00e5ne University Hospital, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hjort","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala 751 85, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Jernberg","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Marko-Varga","sequence":"additional","affiliation":[{"name":"Department of Biomedical, Engineering, Clinical Protein Science & Imaging, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Rezeli","sequence":"additional","affiliation":[{"name":"Department of Biomedical, Engineering, Clinical Protein Science & Imaging, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Spaak","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertil","family":"Lindahl","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala 751 85, Sweden"},{"name":"Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"key":"2021111802325544300_zuaa014-B1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1136\/hrt.2010.197392","article-title":"Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome","volume":"97","author":"Oemrawsingh","year":"2011","journal-title":"Heart"},{"key":"2021111802325544300_zuaa014-B2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/eurheartj\/ehq468","article-title":"Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial","volume":"32","author":"Scirica","year":"2011","journal-title":"Eur Heart J"},{"key":"2021111802325544300_zuaa014-B3","first-page":"1644","article-title":"Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36)","volume":"63","author":"O'Malley","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2021111802325544300_zuaa014-B4","doi-asserted-by":"crossref","first-page":"e002586","DOI":"10.1161\/JAHA.115.002586","article-title":"Multimarker risk stratification in patients with acute myocardial infarction","volume":"5","author":"O'Donoghue","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2021111802325544300_zuaa014-B5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"40","author":"Thygesen","year":"2019","journal-title":"Eur Heart J"},{"key":"2021111802325544300_zuaa014-B6","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1021\/acs.jproteome.7b00235","article-title":"Quantitation of 87 proteins by nLC-MRM\/MS in human plasma: workflow for large-scale analysis of biobank samples","volume":"16","author":"Rezeli","year":"2017","journal-title":"J Proteome Res"},{"key":"2021111802325544300_zuaa014-B7","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1093\/nar\/gkr424","article-title":"Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood","volume":"39","author":"Lundberg","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"2021111802325544300_zuaa014-B8","doi-asserted-by":"crossref","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","article-title":"Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability","volume":"9","author":"Assarsson","year":"2014","journal-title":"PLoS One"},{"key":"2021111802325544300_zuaa014-B9","doi-asserted-by":"crossref","first-page":"D204","DOI":"10.1093\/nar\/gku989","article-title":"Uniprot: a hub for protein information","volume":"43","author":"UniProt","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2021111802325544300_zuaa014-B10","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1161\/ATVBAHA.107.155143","article-title":"Death receptors and their ligands in atherosclerosis","volume":"28","author":"Kavurma","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2021111802325544300_zuaa014-B11","doi-asserted-by":"crossref","first-page":"1752854","DOI":"10.1155\/2016\/1752854","article-title":"Roles and clinical applications of OPG and TRAIL as biomarkers in cardiovascular disease","volume":"2016","author":"Bernardi","year":"2016","journal-title":"Biomed Res Int"},{"key":"2021111802325544300_zuaa014-B12","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ebiom.2017.11.023","article-title":"Elevated markers of death receptor-activated apoptosis are associated with increased risk for development of diabetes and cardiovascular disease","volume":"26","author":"Mattisson","year":"2017","journal-title":"EBioMed"},{"key":"2021111802325544300_zuaa014-B13","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1161\/STROKEAHA.119.024379","article-title":"sTRAIL-R2 (Soluble TNF [Tumor Necrosis Factor]-Related Apoptosis-Inducing Ligand Receptor 2) a marker of plaque cell apoptosis and cardiovascular events","volume":"50","author":"Gon\u00e7alves","year":"2019","journal-title":"Stroke"},{"key":"2021111802325544300_zuaa014-B14","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1177\/2047487317725017","article-title":"GDF-15 and TRAIL-R2 are powerful predictors of long-term mortality in patients with acute myocardial infarction","volume":"24","author":"Skau","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"2021111802325544300_zuaa014-B15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MED.0000000000000294","article-title":"FGF-23 and cardiovascular disease: review of literature","volume":"23","author":"Batra","year":"2016","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2021111802325544300_zuaa014-B16","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1681\/ASN.2017121334","article-title":"Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases: a meta-analysis","volume":"29","author":"Marthi","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2021111802325544300_zuaa014-B17","doi-asserted-by":"crossref","first-page":"640","DOI":"10.7326\/0003-4819-152-10-201005180-00004","article-title":"The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study","volume":"152","author":"Parker","year":"2010","journal-title":"Ann Intern Med"},{"key":"2021111802325544300_zuaa014-B18","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.15190\/d.2019.10","article-title":"Cardiac FGF23: a new player in myocardial infarction","volume":"7","author":"Schumacher","year":"2019","journal-title":"Discoveries (Craiova"},{"key":"2021111802325544300_zuaa014-B19","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/heartjnl-2016-310520","article-title":"Fibroblast growth factor 23 as novel biomarker for early risk stratification after ST-elevation myocardial infarction","volume":"103","author":"Reindl","year":"2017","journal-title":"Heart"},{"key":"2021111802325544300_zuaa014-B20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1186\/s13054-014-0713-8","article-title":"Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial","volume":"18","author":"Fuernau","year":"2014","journal-title":"Crit Care"},{"key":"2021111802325544300_zuaa014-B21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-94-017-7215-0_14","article-title":"The role of CA 125 as tumor marker: biochemical and clinical aspects","volume":"867","author":"Bottoni","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"2021111802325544300_zuaa014-B22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/CRD.0b013e318265f58f","article-title":"Carbohydrate antigen 125: a new biomarker in heart failure","volume":"21","author":"Vizzardi","year":"2013","journal-title":"Cardiol Rev"},{"key":"2021111802325544300_zuaa014-B23","doi-asserted-by":"crossref","first-page":"864","DOI":"10.2459\/JCM.0000000000000051","article-title":"Insights into the clinical implications of carbohydrate antigen 125 as a biomarker of heart failure: a meta-analysis and systematic review of published studies","volume":"15","author":"Zhuang","year":"2014","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2021111802325544300_zuaa014-B24","doi-asserted-by":"crossref","first-page":"e9124","DOI":"10.1590\/1414-431x20199124","article-title":"Carbohydrate antigen 125 predicts pulmonary congestion in patients with ST-segment elevation myocardial infarction","volume":"52","author":"Falc\u00e3o","year":"2019","journal-title":"Braz J Med Biol Res"},{"key":"2021111802325544300_zuaa014-B25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.15171\/jcvtr.2018.17","article-title":"Role of plasma levels of CA-125 in predicting outcome of primary PCI after acute myocardial infarction in male patients","volume":"10","author":"Separham","year":"2018","journal-title":"J Cardiovasc Thorac Res"},{"key":"2021111802325544300_zuaa014-B26","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1373\/clinchem.2016.255174","article-title":"Growth differentiation factor 15 as a biomarker in cardiovascular disease","volume":"63","author":"Wollert","year":"2017","journal-title":"Clin Chem"},{"key":"2021111802325544300_zuaa014-B27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12872-016-0250-2","article-title":"Growth differentiation factor-15 predicts the prognoses of patients with acute coronary syndrome: a meta-analysis","volume":"16","author":"Zhang","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"2021111802325544300_zuaa014-B28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ejhf.980","article-title":"Circulating proteins as predictors of incident heart failure in the elderly","volume":"20","author":"Stenemo","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2021111802325544300_zuaa014-B29","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1053\/euhj.1999.2045","article-title":"Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction","volume":"21","author":"Talwar","year":"2000","journal-title":"Eur Heart J"},{"key":"2021111802325544300_zuaa014-B30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijcard.2009.09.537","article-title":"Predictive value of NT-pro BNP after acute myocardial infarction: relation with acute and chronic infarct size and myocardial function","volume":"147","author":"Mayr","year":"2011","journal-title":"Int J Cardiol"},{"key":"2021111802325544300_zuaa014-B31","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/hrt.2010.198804","article-title":"The Swedish Web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART)","volume":"96","author":"Jernberg","year":"2010","journal-title":"Heart"}],"container-title":["European Heart Journal. Acute Cardiovascular Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/10\/7\/806\/41146965\/zuaa014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/10\/7\/806\/41146965\/zuaa014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T02:52:59Z","timestamp":1637203979000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjacc\/article\/10\/7\/806\/6294758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,6,7]]},"published-print":{"date-parts":[[2021,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjacc\/zuaa014","relation":{},"ISSN":["2048-8726","2048-8734"],"issn-type":[{"value":"2048-8726","type":"print"},{"value":"2048-8734","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,6,7]]}}}